While Bluebird bio Inc has underperformed by -0.24%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, BLUE fell by -79.10%, with highs and lows ranging from $28.60 to $3.56, whereas the simple moving average fell by -59.14% in the last 200 days.
On February 24, 2025, JP Morgan Upgraded Bluebird bio Inc (NASDAQ: BLUE) to Neutral. A report published by JP Morgan on November 15, 2024, Downgraded its rating to ‘Underweight’ for BLUE. BofA Securities also Downgraded BLUE shares as ‘Neutral’, setting a target price of $0.50 on the company’s shares in a report dated November 15, 2024. HSBC Securities December 11, 2023d its ‘Hold’ rating to ‘Reduce’ for BLUE, as published in its report on December 11, 2023. Morgan Stanley’s report from December 08, 2023 suggests a price prediction of $7 for BLUE shares, giving the stock a ‘Equal-Weight’ rating. Cantor Fitzgerald also rated the stock as ‘Neutral’.
Analysis of Bluebird bio Inc (BLUE)
Further, the quarter-over-quarter increase in sales is 391.72%, showing a positive trend in the upcoming months.
Bluebird bio Inc’s future performance can be determined with the help of several well-rounded types of analysis and research techniques, with equity being one of the most influential. The goal here is to ensure that your current return on equity of -295.35% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 0.28, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
The average volume for any stock is also a very valuable indicator of volatility, and BLUE has an average volume of 427.88K. On a monthly basis, the volatility of the stock is set at 8.86%, whereas on a weekly basis, it is put at 8.09%, with a loss of -11.35% over the past seven days. Furthermore, long-term investors anticipate a median target price of $6.50, showing growth from the present price of $4.14, which can serve as yet another indication of whether BLUE is worth investing in or should be passed over.
How Do You Analyze Bluebird bio Inc Shares?
In addition to analyzing the fundamentals, it is also important to look at how many company employees own stock. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 1.08%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 30.80% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
BLUE shares are owned by institutional investors to the tune of 30.80% at present.
